Prodrug composition
OwnerJohn Hilfinger, Wei Sheninventors
Life of this patent
Estimating the term…
Abstract
A prodrug composition is provided which includes a pharmaceutical species and an amino acid having a covalent bond to the pharmaceutical species. A particular pharmaceutical species is adenosine arabinoside, also known as Ara A and by the trade name vidarabine. Ara A prodrugs of the present invention have increased bioavailability compared to the parent compound Ara A. The inventive prodrug is transported from the gastrointestinal lumen by a specific transporter and is enzymatically cleaved to yield Ara A, such that Ara A is delivered to the individual.
Claims19
A composition, comprising:
- a prodrug having the structural formula:
- where R1, R2 and R3 are each independently H, or a substrate for a transporter selected from the group consisting of:
- an amino acid, a dipeptide and a tripeptide, where at least one of R1, R2 and R3 is an amino acid, a dipeptide or a tripeptide;
- or a salt or hydrate thereof.
A composition, comprising:
- a prodrug having the structural formula
- where R1 is an amino acid and where R2 and R3 are both H.
A method of treatment of a subject, comprising:
- administering to a subject in need thereof a therapeutically effective amount of a composition comprising a prodrug having the structural formula:
- where R1, R2 and R3 are each independently H, an amino acid, a dipeptide or a tripeptide, where at least one of R1, R2 and R3 is an amino acid, a dipeptide or a tripeptide;
- and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.